Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.

The device is intended to be a bridge for heart failure patients waiting to receive a full heart transplant.

Cardiologists, electrophysiologists, surgeons and patient representatives all worked together on the updated guidelines, which were published in both the Journal of the American College of Cardiology and Circulation.

Interventional cardiologist David Kandzari, MD, performed the procedure just days after the device received full FDA approval. 

"This practice has been adopted by multiple organ-procurement organizations and is used on thousands of organ donors each year, without ever having been rigorously studied," one researcher said. 

The deal could also include additional clinical and regulatory milestone payments in the years ahead.

The research will focus on ways to improve the utilization of electronic resources among heart failure patients and the doctors who treat them.

Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.

The technology may not be cheap, but new research published in The American Journal of Cardiology suggests the investment is well worth it. 

GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year.